Hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies [Phase 1]
Phase 1 clinical trial evaluating CTX-8371 in patients with advanced malignancies, including Non-Small Cell Lung Cancer and Triple-Negative …
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma [EARLY_Phase 1]
This early-phase trial update describes evaluation of PD-1 inhibitors after CD30 CAR T-cell therapy in patients with relapsed or refractory …
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: First in Human, Dose Escalation, Dose Expansion Study of AUR105 [Phase 1]
AUR105 is Aurigene's first-in-human Phase 1 study with dose-escalation and dose-expansion cohorts in adults with solid tumors and lymphomas.…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia [Phase 2]
A Phase 2 clinical trial evaluating ascorbic acid with chemotherapy for relapsed/refractory lymphoma, clonal cytopenia of undetermined signi…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma [Phase 2]
Phase II clinical trial evaluating pembrolizumab plus the GVD regimen as second-line therapy for relapsed or refractory Hodgkin lymphoma, cu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies [Phase 2]
Phase 2 study evaluating a two-step reduced-intensity conditioning approach for bone marrow transplant in adults with hematologic malignanci…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors [NA]
This completed clinical trial evaluated the effectiveness and implementation of an electronic health record tool to assess heart health amon…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma [Phase 2]
This is a Phase 2 clinical trial update evaluating a PET-adapted combination of Brentuximab Vedotin and Pembrolizumab with doxorubicin and d…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating CD30-targeted CAR T-cells after autologous stem cell transplant in patient…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes autologous stem cell transplant followed by polatuzumab vedotin for patients with various B-cell…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma [Phase 2]
A Phase II clinical trial is evaluating the combination of azacitidine and pembrolizumab for patients with relapsed or refractory Hodgkin ly…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial update. It evaluates a conditioning strategy using chemotherapy, total body irradiation, and post-transpl…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
This clinical trial update describes biospecimen procurement for the Center for Immuno-Oncology immunotherapy protocols. It covers recruitin…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas [Phase 1]
Phase 1 clinical trial update for constitutive IL7R (C7R) modified banked allogeneic CD30.CAR EBVSTs in CD30-positive lymphomas, currently r…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma [Phase 1]
A Phase 1 clinical trial is evaluating the combination of nivolumab with ASTX727 (decitabine/cedazuridine) in relapsed or refractory B-cell …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
An ongoing clinical trial update evaluating brentuximab vedotin in pediatric participants with Hodgkin lymphoma, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors [Phase 1]
A Phase 1 clinical trial evaluating HCB301, an engineered Sirpα fusion with anti-PD-L1 and TGF-β activity, in patients with selected advance…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial [NA]
Clinical trial evaluating whether interrupting sedentary time can improve cardiometabolic health and chemotherapy-related toxicity in patien…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial investigates brentuximab vedotin and nivolumab, with or without ipilimumab, for relapsed or refractory Hodgkin lymphoma …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Prospective collection, storage, and reporting of data on patients undergoing hematopoietic stem cell transplantation using a standard prepa…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
A multicenter protocol to improve access and distribution of unlicensed cryopreserved cord blood units, with the study currently recruiting.…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Phase Ib of L-NMMA and Pembrolizumab [Phase 1]
This completed Phase 1 trial evaluated the combination of L-NMMA with pembrolizumab across multiple cancers, with results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation [Phase 1]
This Phase 1 trial evaluated donor-derived anti-CD19 CAR-T cells in patients with recurrent or persistent B-cell malignancies after allogene…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study [NA]
Completed clinical trial evaluating a geriatric optimization plan to improve survival in older adults undergoing allogeneic hematopoietic ce…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies [Phase 1]
Phase 1 trial evaluating an anti-CD30 bispecific antibody (AATC) in relapsed/refractory CD30-positive hematologic malignancies; currently re…